Sharemaestro Newsreel

Labcorp SVP, Chief Accounting Officer Peter J. Wilkinson disposes of 1,420 shares worth $439,103.37

Peter J. Wilkinson, SVP and Chief Accounting Officer at Labcorp, sold 1,420 shares of the company's stock on August 3rd at approximately $309.23 per share, totaling $439,103.37. Prior to this, Wilkinson exercised 1,338 non-qualified stock options at $209.25 per share. Following these transactions, he …

Mettler-Toledo International (NYSE:MTD) Insider Sells $342,513.60 in Stock

Mettler-Toledo International insider Gerry Keller sold 240 shares of company stock for $342,513.60, reducing his direct ownership by 48.1%. The company recently reported quarterly EPS of $11.46, surpassing analyst estimates, with revenue rising 4.5% year over year to $1.03 billion. Despite positive earnings, analyst …

Mettler-Toledo International (NYSE:MTD) CFO Shawn Vadala Sells 2,240 Shares of Stock

Mettler-Toledo International (NYSE:MTD) CFO Shawn Vadala recently sold 2,240 shares of the company's stock for over $3.2 million, reducing his direct holdings by 28.65%. This transaction comes as the company reported better-than-expected quarterly earnings with an EPS of $11.46 and revenue of $1.03 billion, …

Mettler Toledo International Insider Sold Shares Worth $342,514, According to a Recent SEC Filing

An insider at Mettler Toledo International recently sold shares valued at $342,514, as detailed in a recent SEC filing. This transaction involved a significant sale of company stock by an insider. The specific details of the sale are publicly available through the SEC filing.

Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792

Jefferies has increased its price target for IDEXX Laboratories (IDXX) to $795 from the previous $792, while maintaining a Hold rating on the stock. This adjustment reflects a modest change in the firm's outlook for the company.

Charles River Laboratories International Up Nearly 12%, on Track for Highest Close Since April 2024 -- Data Talk

Charles River Laboratories International (CRL) is experiencing a significant surge, with its stock up nearly 12% and on track for its highest close since April 1, 2024. The company's stock is currently trading at $262.05, marking a 31.37% increase year-to-date and making it the …

Gerry Keller At Mettler-Toledo Intl Capitalizes: Options Exercised, Resulting In $172K

Gerry Keller, Head Process Analytics at Mettler-Toledo Intl (NYSE: MTD), recently exercised stock options for 240 shares valued at $172,125. The company's financials show a positive revenue trend with a 4.48% growth rate but a high debt-to-equity ratio of 164.7. Mettler-Toledo Intl has a …

Prenetics Global (PRE) director converts 2,001 RSUs to stock

Prenetics Global director Hudson Blake Leogrande converted 2,001 Restricted Stock Units (RSUs) into 2,001 Class A Ordinary Shares on August 4, 2026, at an exercise price of $0.0000 per share. These RSUs had vested on June 4, 2026, under the company's 2022 Share Incentive …

Mettler Toledo director Natalia Shuman-Fabbri files initial beneficial ownership statement

Mettler Toledo director Natalia Shuman-Fabbri has filed her initial Form 3 beneficial ownership statement, dated August 3. This news brief was generated by Public Technologies (PUBT) using AI and is based on original content published by Mettler Toledo International Inc. via the SEC's EDGAR …

Charles River Laboratories stock hits 52-week high at $266.00 By Investing.com

Charles River Laboratories International Inc. (CRL) stock reached a new 52-week high of $266.00, surpassing its previous high of $242.73, and now boasts a market capitalization of $11.28 billion. This surge reflects a 39.78% price return over the past year and a 27.45% gain …

Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety (NASDAQ:TWST)

Barclays Adjusts Price Target on Revvity to $115 From $105, Maintains Equalweight Rating

Barclays has increased its price target for Revvity (RVTY) shares to $115 from $105, while maintaining an Equalweight rating on the stock. This adjustment reflects an updated outlook from the analyst firm. The article also briefly mentions other analysts like Bernstein, Evercore ISI, and …

Citigroup Adjusts Price Target on IDEXX Laboratories to $670 From $650

Citigroup has raised its price target for IDEXX Laboratories (IDXX) from $650 to $670, as reported on August 5, 2026. This adjustment follows other recent analyst updates for the company, including Jefferies increasing its target to $795 and UBS raising its target to $670. …

Charles River Laboratories International, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:CRL) 2026-08-05

Charles River Laboratories International (CRL) exceeded Q2 expectations, driven by improved demand in its Discovery and Safety Assessment (DSA) business and strong manufacturing performance. The company raised its full-year guidance for revenue, earnings, and free cash flow, anticipating a gradual recovery in biopharmaceutical demand. …

Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 19,040 Shares

Tobin Juvenal, Chief Commercial Officer of Castle Biosciences (CSTL), sold 19,040 shares of the company's stock for approximately $556,158. This transaction is part of a broader trend of insider selling at Castle Biosciences, with 50 insider sells and zero buys over the past year. …

Is Mettler-Toledo International (MTD) Fully Priced After A 18% Gain?

Price to sales forward of CareDx, Inc. – LS:A118WG

This article provides financial information for CareDx, Inc. (A118WG) from TradingView, focusing on its price to sales forward metric. It indicates that no trades were recorded and the market was closed. The content is primarily a data page with various links to other financial …

Labcorp Holdings (NYSE: LH) CAO sells 1,420 shares after exercising options

Peter J. Wilkinson, SVP and Chief Accounting Officer of Labcorp Holdings Inc., exercised 1,338 non-qualified stock options at $209.25 per share and subsequently sold 1,420 common shares in open-market transactions at prices between $309.22 and $309.2311. This transaction was reported in a Form 4 …

UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $670

UBS has reiterated its Hold rating on IDEXX Laboratories Inc (IDXX.US) and increased its price target to $670. This adjustment reflects the firm's updated valuation for the company.

XWELL CEO Ezra Ernst Resigns as Director, Keeps CEO Role

XWELL (NASDAQ: XWEL) announced the appointment of Gerard Reid to its Board of Directors, effective immediately, bringing extensive experience in energy transition and capital markets. Concurrently, Ezra Ernst resigned from the Board to concentrate fully on his responsibilities as the company's President and Chief …

Check-Cap (MBAI) Sets Eight-Week Target for MBody AI Merger

Check-Cap Ltd. (NASDAQ: MBAI) has filed its Form F-1 and now anticipates its merger with MBody AI Corp. to conclude within the next eight weeks, moving up its previously projected timeline to the third quarter of 2026. Both companies' shareholders have approved the merger, …

Guardant Health (GH) Sees 48% Growth as Its Cancer Tests Gain Momentum

Guardant Health (NASDAQ:GH) experienced 48% revenue growth year-over-year, driven by increased adoption of its Guardant360 cancer treatment selection test and the Shield colorectal cancer blood test. The company's prospects are further boosted by the FDA approval of Guardant360 Liquid CDx and the American Cancer …

Charles River (CRL) Stock Jumps As Margin Repair Meets Valuation Doubt

Charles River Laboratories International (CRL) saw its stock jump 11.4% after Q2 non-GAAP earnings led to lifted full-year guidance, driven by portfolio cleanup and improved margins. While bulls see a clear path to margin-led repair despite flat organic revenue, bears remain concerned about structural …

(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $11.15 - $11.45, vs. FactSet Est of $11.11

Charles River Laboratories (CRL) has released its adjusted EPS guidance for 2026, projecting a range of $11.15 to $11.45. This forecast surpasses the FactSet estimate of $11.11. The announcement was made on August 5, 2026, and follows recent updates to the company's earnings guidance …

CRL: 2Q26 organic revenue and EPS beat outlook, prompting raised 2026 guidance and margin expansion

Charles River Laboratories (CRL) reported strong Q2 2026 results, with organic revenue and non-GAAP EPS surpassing expectations due to increased demand in DSA and improved Manufacturing performance. This led to a raised 2026 guidance, supported by strategic divestitures and technology investments aimed at enhancing …

Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom

Eli Lilly's new oral GLP-1 treatment, Foundayo, reported Q2 sales of $98 million, significantly trailing Novo Nordisk's rival Wegovy pill. Despite this, positive trends for Foundayo in the U.S. and strong international potential were noted. Meanwhile, Lilly's injectable diabetes and obesity medicines, Mounjaro and …

Charles River Labs (NYSE: CRL) swings to Q2 loss but raises 2026 guidance

Charles River Laboratories International, Inc. (NYSE: CRL) reported a Q2 2026 revenue of $1.00 billion, a 2.7% decrease year-over-year, and swung to a GAAP net loss of $(1.5) million, or $(0.03) per share, primarily due to divestiture losses. Despite the loss, the company raised …

Veracyte (NASDAQ:VCYT) Shows Affordable Growth Potential

Agilent Technologies, Inc. $A Shares Purchased by Bank of America Corp DE

Bank of America Corp DE increased its stake in Agilent Technologies, Inc. by 19.2% in the first quarter, now holding 1.63 million shares valued at $186.3 million. Agilent Technologies also received favorable analyst ratings, with a "Moderate Buy" consensus and an average price target …

Revvity posts solid Q2 2026 earnings growth

TD Cowen upgrades Waters stock rating to buy, raises price target to $475

TD Cowen has upgraded Waters Corp. (NYSE:WAT) from Hold to Buy and increased its price target to $475 from $408, citing strong second-quarter results and expectations for continued high-single-digit percentage growth. The firm believes the stock, currently trading near its 52-week high, can support …

Janus Henderson Group PLC Makes New Investment in Qiagen N.V. $QGEN

Janus Henderson Group PLC has made a new investment in Qiagen N.V., purchasing 366,661 shares valued at approximately $14.6 million, giving it a 0.18% stake. Other institutional investors have also adjusted their holdings, with institutional ownership of Qiagen reaching 70%. Analyst sentiment for Qiagen …

Evercore ISI Adjusts Price Target on Revvity to $126 From $125, Maintains Outperform Rating

Evercore ISI has increased its price target for Revvity (RVTY) to $126 from $125, while reaffirming its "Outperform" rating on the stock. This adjustment reflects continued positive sentiment from the analyst firm regarding Revvity's financial prospects and market position. The update follows recent financial …

Thermo Fisher Scientific to Present at Raymond James Annual Institutional Investors Conference

Thermo Fisher Scientific Inc. (NYSE: TMO) announced that its chairman, president, and CEO, Marc N. Casper, will present at the Raymond James Institutional Investors Conference on March 3, 2026, at 9:15 a.m. ET. A live webcast of the presentation will be available on the …

Revvity Inc reports results for the quarter ended June 30 - Earnings Summary

Revvity Inc has released its earnings summary for the quarter that ended on June 30. The article, provided by Refinitiv and distributed through TradingView, is an earnings report. Full access to the complete article and other news sources is available through a TradingView subscription.

Revvity (RVTY) Stock Premium Faces Pressure From Thin Margins

Revvity (RVTY) stock experienced a 3% dip despite exceeding Q2 earnings expectations, raising concerns about its high P/E ratio of 52.4x and recent squeeze in net profit margin to 8.2%. The article explores both the bullish arguments, such as organic growth in diagnostics and …